Bio-Techne Co. (NASDAQ:TECH) CFO James Hippel sold 10,000 shares of Bio-Techne stock in a transaction on Monday, January 11th. The stock was sold at an average price of $333.63, for a total transaction of $3,336,300.00. Following the sale, the chief financial officer now owns 19,137 shares of the company’s stock, valued at $6,384,677.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

James Hippel also recently made the following trade(s):

  • On Wednesday, November 11th, James Hippel sold 7,391 shares of Bio-Techne stock. The stock was sold at an average price of $307.05, for a total transaction of $2,269,406.55.
  • On Monday, November 9th, James Hippel sold 3,600 shares of Bio-Techne stock. The stock was sold at an average price of $309.79, for a total transaction of $1,115,244.00.
  • On Thursday, November 5th, James Hippel sold 8,809 shares of Bio-Techne stock. The stock was sold at an average price of $286.12, for a total transaction of $2,520,431.08.

NASDAQ TECH opened at $330.58 on Thursday. Bio-Techne Co. has a 1 year low of $155.17 and a 1 year high of $342.98. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.88 and a quick ratio of 3.92. The company has a fifty day moving average of $314.12 and a 200 day moving average of $278.00. The company has a market capitalization of $12.76 billion, a PE ratio of 57.10, a P/E/G ratio of 7.83 and a beta of 0.98.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.33. Bio-Techne had a net margin of 31.04% and a return on equity of 11.94%. The company had revenue of $204.20 million during the quarter, compared to analysts’ expectations of $185.04 million. During the same quarter in the previous year, the company earned $1.06 earnings per share. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. Research analysts expect that Bio-Techne Co. will post 4.83 earnings per share for the current year.

TECH has been the subject of several research reports. Atlantic Securities initiated coverage on shares of Bio-Techne in a research note on Wednesday, September 30th. They set an “overweight” rating and a $365.00 price objective for the company. KeyCorp initiated coverage on shares of Bio-Techne in a research note on Monday, November 9th. They set a “sector weight” rating and a $340.00 price objective for the company. Robert W. Baird lifted their price objective on shares of Bio-Techne from $289.00 to $320.00 and gave the stock an “outperform” rating in a research note on Friday, November 6th. BidaskClub upgraded shares of Bio-Techne from a “sell” rating to a “hold” rating in a research report on Friday, October 16th. Finally, SVB Leerink boosted their target price on shares of Bio-Techne from $285.00 to $320.00 and gave the company an “outperform” rating in a research report on Friday, November 6th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $297.55.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TECH. Raymond James Trust N.A. increased its position in shares of Bio-Techne by 18.9% in the 4th quarter. Raymond James Trust N.A. now owns 1,466 shares of the biotechnology company’s stock valued at $466,000 after purchasing an additional 233 shares during the last quarter. Louisiana State Employees Retirement System grew its position in shares of Bio-Techne by 1.0% in the 4th quarter. Louisiana State Employees Retirement System now owns 9,700 shares of the biotechnology company’s stock valued at $3,080,000 after buying an additional 100 shares during the last quarter. Wetherby Asset Management Inc. purchased a new position in shares of Bio-Techne in the 3rd quarter valued at $257,000. Strs Ohio grew its position in shares of Bio-Techne by 7.4% in the 3rd quarter. Strs Ohio now owns 7,865 shares of the biotechnology company’s stock valued at $1,948,000 after buying an additional 542 shares during the last quarter. Finally, S&CO Inc. purchased a new position in shares of Bio-Techne in the 3rd quarter valued at $1,640,000. 94.49% of the stock is owned by institutional investors.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies.

Featured Article: Hang Seng Index (HSI)

Insider Buying and Selling by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.